GE HealthCare AI Suite vs ScreenPoint Transpara

ScreenPoint says Transpara works with 2D and 3D mammography systems from any maker and identifies it as the AI in the MASAI screening trial. In ScreenPoint's summary, the Lancet report on over 105,000 women gave sensitivity of 80.5% against 73.8% for standard double reading at 98.5% specificity, and the paper is academic work from Lund University. FDA lists eight Transpara 510(k)s, the newest K260898 from August 2026, and one of the eight is Transpara Density (K232096). MASAI ran in Swedish double-reading screening, so how far it carries to US single-read programs is open.

GE HealthCare frames its AI as intelligence embedded in devices plus operational tools, led by CareIntellect, and its cleared pieces include MR reconstruction in AIR Recon DL (K213717). A breast screening program choosing reader support for its mammograms is a Transpara decision, since GE's AI sits on the scanner side. A hospital planning an MR and X-ray tender takes GE's AI as part of or an option on that order.